CHELSEA O'NEILL: Open Payments
NPI 1366078230 · ROYAL OAK, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,107 in 56 payments from 10 companies in 2025. Trend: 2023 $966 · 2024 $1,323 · 2025 $1,107
Food & beverage: $1,107
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 15 | $284 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 11 | $192 |
| Orexo US, Inc. | 10 | $181 |
| Indivior Inc. | 6 | $135 |
| Lundbeck LLC | 4 | $103 |
| Braeburn Inc. | 4 | $92 |
| Axsome Therapeutics, Inc. | 2 | $57 |
| Otsuka America Pharmaceutical, Inc. | 2 | $35 |
| Neos Therapeutics, LP | 1 | $15 |
| Lilly USA, LLC | 1 | $14 |
Products named: CAPLYTA, Zubsolv, MAVYRET, REXULTI, SUBLOCADE, VRAYLAR, BRIXADI, Auvelity.
Industry payments across MI — which companies pay providers there.
